Your browser doesn't support javascript.
loading
Data against a Common Assumption: Xenogeneic Mouse Models Can Be Used to Assay Suppression of Immunity by Human MSCs.
Prockop, Darwin J; Oh, Joo Youn; Lee, Ryang Hwa.
Affiliation
  • Prockop DJ; Institute for Regenerative Medicine, College of Medicine, Texas A&M University, 1114 TAMU, 206 Olsen Boulevard, College Station, TX 77845, USA. Electronic address: prockop@medicine.tamhsc.edu.
  • Oh JY; Department of Ophthalmology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea; Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea.
  • Lee RH; Institute for Regenerative Medicine, College of Medicine, Texas A&M University, 1114 TAMU, 206 Olsen Boulevard, College Station, TX 77845, USA.
Mol Ther ; 25(8): 1748-1756, 2017 08 02.
Article in En | MEDLINE | ID: mdl-28647464
ABSTRACT
Much of what we know about immunology suggests that little is to be gained from experiments in which human cells are administered to immunocompetent mice. Multiple reports have demonstrated that this common assumption does not hold for experiments with human mesenchymal stem/stromal cells (hMSCs). The data demonstrate that hMSCs can suppress immune responses to a variety of stimuli in immunocompetent mice by a range of different mechanisms that are similar to those employed by mouse MSCs. Therefore, further experiments with hMSCs in mice will make it possible to generate preclinical data that will improve both the efficacy and safety of the clinical trials with the cells that are now in progress.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Immunomodulation / Mesenchymal Stem Cells / Immune Tolerance Limits: Animals / Humans Language: En Year: 2017 Type: Article

Full text: 1 Database: MEDLINE Main subject: Immunomodulation / Mesenchymal Stem Cells / Immune Tolerance Limits: Animals / Humans Language: En Year: 2017 Type: Article